Physician profile
Samuel Kim
NPI 1629386388
$23,732.88
in general payments reported to CMS, 2019-2025
41 companies · $3,055 in 2025
The $3,055 reported for 2025 was more than what 77% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,383 · 2020: $2,106 · 2021: $3,917 · 2022: $3,953 · 2023: $2,499 · 2024: $2,821 · 2025: $3,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,216 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,215.57 |
| Education | $158.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,198.55 | 2019-2025 | |
| Horizon Therapeutics Plc | $3,554.82 | 2019-2023 | Krystexxa |
| Amgen INC. | $2,905.59 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Janssen Biotech, INC. | $2,362.87 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $1,708.39 | 2019-2025 | |
| Ucb, INC. | $1,410.66 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $899.82 | 2019-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $808.60 | 2019-2025 | Orencia |
| Radius Health, INC. | $758.30 | 2019-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $653.62 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $605.88 | 2019-2025 | Taltz, Zepbound, Olumiant |
| Pfizer INC. | $579.89 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $499.11 | 2020-2025 | Acthar |
| Genentech USA, INC. | $433.82 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.16 | 2019-2023 | Ofev |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $274.85 | 2019-2025 | |
| Genzyme Corporation | $266.66 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $263.96 | 2020-2024 | Strensiq |
| Aurinia Pharma U.S., INC. | $220.05 | 2021-2025 | Lupkynis |
| Pacira Therapeutics, INC. | $195.46 | 2019-2021 | |
| Organon LLC | $105.20 | 2021-2025 | Hadlima, Renflexis |
| Mallinckrodt Enterprises LLC | $98.88 | 2019 | |
| Invivyd INC | $89.62 | 2025 | Pemgarda |
| Ani Pharmaceuticals, INC. | $63.27 | 2023-2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $61.44 | 2021-2024 | Rybelsus, Ozempic |
| Assertio Therapeutics, INC. | $50.09 | 2019 | |
| Csl Behring | $49.62 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $40.99 | 2019-2020 | |
| Depuy Synthes Sales INC. | $26.41 | 2019 | |
| Sanofi-Aventis U.S. LLC | $23.38 | 2021 | |
| Sequel Med Tech, LLC | $20.77 | 2025 | Twiist |
| Ultragenyx Pharmaceutical INC. | $20.62 | 2020 | |
| Kyowa Kirin, INC. | $20.08 | 2024 | Crysvita |
| Fresenius Kabi USA, LLC | $19.15 | 2023 | |
| Ascendis Pharma Endocrinology INC | $18.14 | 2025 | Yorvipath |
| Sandoz INC. | $17.70 | 2024 | Hyrimoz |
| Bioventus LLC | $17.37 | 2022 | |
| Tonix Medicines, INC. | $16.02 | 2025 | Tonmya |
| Daiichi Sankyo INC. | $13.76 | 2020 | |
| Zimmer Biomet Holdings, INC. | $13.68 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $9.63 | 2025 | Uptravi, Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.